Celgene enforces its Revlimid® patents against Zydus Pharmaceuticals under Hatch-Waxman Act
Client(s) Celgene Corporation
Jones Day is representing Celgene Corporation in a patent litigation against Zydus Pharmaceuticals and Cadila Healthcare over Revlimid®, Celgene's blockbuster drug for treating multiple myeloma and other cancers.
Celgene Corp. v. Zydus Pharmaceuticals (USA) Inc., et al., No. 2-17-cv-02528 (D.N.J.)